COLUMBIA, Md., Aug. 18 /PRNewswire-FirstCall/ -- Martek
Biosciences Corporation (Nasdaq: MATK) announced today that it
intends to release the results of its third quarter of fiscal 2010
on Wednesday, September 1, 2010, at
approximately 4:00 p.m. Eastern Time
(ET). At 4:45 p.m. ET Martek
will conduct a conference call to discuss these results with
investors. All interested parties may listen to the call live
via webcast by visiting Martek's web site at
http://investors.martek.com.
An archived webcast of the conference call will be available on
the Martek's website for thirty days. In addition, a recorded
playback of the call will be available for one week and can be
accessed by calling 800-633-8284 or 402-977-9140 and entering pass
code 21479068.
Martek Biosciences Corporation is a leader in the innovation,
development, production and sales of high-value products from
microbial sources that promote health and wellness through
nutrition. The company is the world's leading provider of algal DHA
omega-3 with its flagship product, life'sDHA™, a sustainable and
vegetarian source of algal DHA omega-3 important for brain, heart
and eye health throughout life, for use in foods, beverages, infant
formula, and supplements. The company also produces life'sARA™
(arachidonic acid), an omega-6 fatty acid, for use in infant
formula and growing up milks. Additionally, Martek's subsidiary,
Amerifit Brands, develops, markets and distributes branded consumer
health and wellness products in major mass, club, drug, grocery and
specialty stores and holds leading brand positions in all of its
key product categories. For more information on Martek Biosciences,
visit http://www.martek.com/. For a complete list of life'sDHA™ or
life'sARA™ products, visit http://www.lifesdha.com/. For more
information about Amerifit Brands, visit www.amerifit.com.
Sections of this release contain forward-looking statements.
These statements are based upon numerous assumptions which Martek
cannot control and involve risks and uncertainties that could cause
actual results to differ. These statements should be understood in
light of the risk factors set forth in the company's filings with
the Securities and Exchange Commission, including, but not limited
to, the company's Form 10-K for the fiscal year ended October 31, 2009 and other filed reports on Form
10-K, Form 10-K/A, Form 10-Q and Form 8-K.
Contact:
|
Kyle Stults
|
|
|
Investor Relations
|
|
|
(410) 740-0081
|
|
|
|
|
|
Cassie France-Kelly
|
|
|
Public Relations
|
|
|
(410) 740-0081
|
|
|
|
SOURCE Martek Biosciences Corporation
Copyright . 18 PR Newswire